On November 1, 2023 Oblique Therapeutics reported its Interim report 1 July to 30 September 2023 (Press release, Oblique Therapeutics, NOV 1, 2023, https://obliquet.com/wp-content/uploads/2023/11/delarsrapport-q3-2023-oblique-therapeutics-ab.pdf [SID1234640429]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During November 2023, Kinnate Biopharma presented the corporate presentation (Presentation, Kinnate Biopharma, NOV 1, 2023, View Source [SID1234639304]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 1, 2023 Kyowa Hakko Kirin reported its Consolidated Financial Summary (IFRS) Fiscal 2023 Third Quarter (Press release, Kyowa Hakko Kirin, NOV 1, 2023, View Source [SID1234638996]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 1, 2023 Ono reported its consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2024 (Filing, 3 mnth, SEP 30, Ono, 2023, NOV 1, 2023, View Source [SID1234638493]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 1, 2023 Hanmi reported its third quarter 2023 results (Presentation, Hanmi, NOV 1, 2023, View Source [SID1234638478]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!